A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Prostate Cancer

Interventions

DRUG

Aplidin (plitidepsin)

Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.

Trial Locations (2)

Seattle Cancer Care Alliance, Seattle

University of Michigan Comprehensive Cancer Center, Ann Arbor